Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 48th Annual Midwinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 48 th Annual Midwinter Meeting, taking place on February 22-26, 2025, in Orlando, Florida, USA.
Laurent Désiré, Ph.D., Head of Preclinical Development at Sensorion, and the team of Professor Christine Petit, Professor at the Hearing Institute, an Institut Pasteur center, at the IHU reConnect, and Professor Emeritus at the Collège de France, Winner of the Kavli Prize in 2018, will co-present the following posters during the ARO meeting:
Presentation type: Poster Presentation
Title: GJB2-GT, a Novel Adeno Associated Vector-Based Gene Therapy as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A)
Date: Sunday, February 23, 2025
Time: 1.30pm – 3pm ET
Room: Peninsula Ballroom
Presentation type: Poster Presentation
Title: GJB2 Gene Therapy-Response of Two Pre-Clinical Mouse Models of the Most Frequent Form of Human deafness, DFNB1
Date: Sunday, February 23, 2025
Time: 1.30pm – 3pm ET
Room: Peninsula Ballroom
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
Sensorion's portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion's clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, has completed in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.
Label:
SENSORION
FR0012596468
Mnemonic: ALSEN
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
[email protected] Relations
Ulysse Communication
Bruno Arabian / 00 33(0)6 87 88 47 26
[email protected] Entz / 00 33 (0)6 33 67 31 54
[email protected]
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE FLORIDA
SOURCE: Sensorion
Copyright Business Wire 2025.
PUB: 02/12/2025 05:30 AM/DISC: 02/12/2025 05:29 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Is Energy Transfer the All-American Dividend Stock for You? Consider This High-Yielder Instead.
Energy Transfer has a lofty 7.4% yield backed by an inherently domestic business. The midstream giant has made some decisions that should leave conservative investors with trust issues. Enterprise Products Partners' 6.9% yield will likely be a better fit for most investors. 10 stocks we like better than Energy Transfer › Dividend investors are always trying to maximize yield, but that requires extra consideration on the risk front. A high yield that isn't backed by a reliable company could leave you in the lurch and, likely, at the worst possible time. This is why investors looking at Energy Transfer (NYSE: ET) and its lofty 7.5% distribution yield will probably be better off taking a little less yield and choosing Enterprise Products Partners (NYSE: EPD) instead. Here's why. Energy Transfer and Enterprise are two of the largest midstream companies in North America. They both hail from the United States and generate most of their business from the country. The truth is, owning energy infrastructure assets like pipelines essentially forces these two businesses to be American at heart. After all, you can't move oil around the United States on a pipeline that gets built in Europe. That pipeline has to get built on U.S. soil. The midstream is actually the most boring segment of the overall energy sector. That's because businesses like Energy Transfer and Enterprise charge fees for the use of their assets. Although the oil, natural gas, and other products that flow through the system may have volatile prices, midstream companies don't really care about the price of what they move. They just care about the volume of product they move. The higher the volume, the higher the toll-like revenues they generate. Given the importance of energy to the global economy, demand for oil and natural gas tends to remain fairly robust even when commodity prices are weak. Even recessions don't materially diminish demand, since the world would, literally, stop in its tracks without oil and natural gas. From this perspective, Energy Transfer and Enterprise Products Partners are on equal footing. Here's the thing: Energy Transfer doesn't have the same history of treating its investors well as Enterprise does. That difference is why conservative income investors should be happy to trade down to Enterprise's 6.9% yield. The first big issue happened in 2016, during a time when oil prices were weak. At that point, Energy Transfer agreed to buy peer Williams. It got cold feet, warning that completing the deal would require taking on too much debt and could also force a dividend cut. It was the right decision to scuttle the deal. The problem was the way in which it achieved that end. The company sold convertible securities, with a huge portion going to the then-CEO. It appears that the convertible securities would have protected the CEO from the effect of a dividend cut, had a dividend cut been needed. In the end, Energy Transfer got out of the Williams deal, but that convertible decision should leave a bad taste in investors' mouths. Then, in 2020, when the energy industry was hit hard by demand declines around the coronavirus pandemic, Energy Transfer cut its distribution. Again, the decision was probably the right one for the business, which used the freed-up cash to strengthen its balance sheet. But income investors took it on the chin, and that's the key takeaway here. During the last two big energy industry downturns, when income investors were likely hoping for consistency, they had to worry about, and actually experience, income declines if they owned Energy Transfer. Enterprise Products Partners didn't cut its distribution in 2016 or in 2020. It didn't put out any warnings that such an event was possible. It just operated its reliable cash flow generating business. Along the way, it delivered distribution increases. At this point, the U.S. midstream giant has increased its distribution for 26 consecutive years. While trust might be a troubling issue with Energy Transfer, it isn't with Enterprise Products Partners. The long streak of putting unitholders first is a core reason to like Enterprise Products Partners, but it isn't the only reason. Other good reasons to like this midstream giant are its investment grade rated balance sheet, and the 1.7x over that its distributable cash flow covered its distribution in 2024. These are both signs of management's commitment, since they mean there's a lot of leeway before a distribution cut would be in the cards at Enterprise Products Partners. Put it all together, and most investors will probably be better off with all-American Enterprise over all-American Energy Transfer. Before you buy stock in Energy Transfer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Energy Transfer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy. Is Energy Transfer the All-American Dividend Stock for You? Consider This High-Yielder Instead. was originally published by The Motley Fool
Yahoo
16 hours ago
- Yahoo
Sandisk Announces Participation in Investor Conference
MILPITAS, Calif., June 07, 2025--(BUSINESS WIRE)--Sandisk Corporation (NASDAQ: SNDK) announced today that management will participate at the Mizuho Technology Conference 2025 on Wednesday, June 11, at 8:15 a.m. PT / 11:15 a.m. ET. The management presentation will be available as a live webcast, accessible through Sandisk's Investor Relations website at An archived replay will be accessible through the website after the conclusion of the presentation. About Sandisk Sandisk (Nasdaq: SNDK) delivers innovative Flash solutions and advanced memory technologies that meet people and businesses at the intersection of their aspirations and the moment, enabling them to keep moving and pushing possibility forward. Follow Sandisk on Instagram, Facebook, X, LinkedIn, Youtube. Join TeamSandisk on Instagram. Sandisk and the Sandisk logo are registered trademarks or trademarks of Sandisk Corporation or its affiliates in the U.S. and/or other countries. © 2025 Sandisk Corporation or its affiliates. All rights reserved. View source version on Contacts Company Contacts: Investors: investors@ Media: mediainquiries@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Treasury Options Skew June 2025
Implied volatility in options on Treasury futures has drifted lower since April, but the skew—particularly in the belly of the curve—remains a focal point. As traders prepare for a data-heavy June, including Non-Farm Payrolls, CPI and the FOMC, the behavior of skew and CVOL in the Ultra 10-Year (UXY) futures complex offers a revealing lens into how rate risk is being priced. Downside skew in Treasury options—especially on 5-Year (FV), 10-Year (TY) and Ultra 10-Year (UXY) futures—remains elevated. TYVY, the CVOL Index for 10-Year Treasury options, has declined from April highs but is still holding in the 115–120 range. Key macro events ahead: Non-Farm Payrolls – Friday, June 6 . Consumer Price Index (CPI) – Wednesday, June 12. FOMC Statement – Wednesday, June 18, 2:00 p.m. ET; press conference at 2:30 p.m. ET. PCE Price Index – Friday, June 27. Despite the decline in overall volatility, downside skew remains persistent, particularly in UXY and FV options. Traders continue to assign higher premiums to puts relative to calls, reflecting structural demand for downside hedges or latent concerns about fiscal risk, policy missteps or supply shocks. As we approach the June 6 jobs report, and especially the June 18 FOMC decision, this skew could be tested. Traders can use CVOL to see TVL or volatility indices for 2-, 5-, 10-Year and Bond futures. For volatility on options like the growing option volume on Ultra 10-Year futures consider QuikVol's QuikSkew analytics. The 2s10s curve steepened in May, reviving interest in conditional curve trades using options to express directional views on curve shape. Options are increasingly being used to express conditional curve trades. Call spreads in FV versus put spreads in UXY. Butterfly structures around inflection points in UXY to capture steepening potential without excessive Vega exposure. TYVY skew, built on deep liquidity from options on 10-Year Note futures, supports this theme. Depending on one's risk management strategy, options on 10-Year Note futures or options on Ultra 10-Year futures retain more downside premium relative to other tenors. We have expanded our suite of Treasury options with the addition of Tuesday and Thursday expiries, significantly enhancing the flexibility of short-dated hedging strategies. This update allows market participants to position tactically around high-impact economic releases such as Non-Farm Payrolls, CPI and FOMC decisions, by accessing expiries available every trading day of the week, two weeks forward. This enhancement is especially valuable in environments with compressed risk windows, intraday volatility bursts, or when event timing doesn't align neatly with the traditional Monday/Wednesday/Friday expiration schedule. The change was detailed in CME Group SER-9566R. With the macro spotlight on June 6 and June 18, options on Treasury futures offer deep insight into how rate risk is being repriced. Skews in UXY options, the behavior of TVL and renewed activity in curve-based option structures all point to a market that sees risk beneath the surface. Whether you're watching TVL or the new Tuesday and Thursday expiries, June will be a month to track the message inside the vol surface. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. CME Group Inc. does not have control over the content, accuracy, quality, or legality, of any third-party product, service, or content advertised on this webpage. The presence of such advertisements on this webpage does not signify any association, partnership, or endorsement of the third-party or its content by CME Group Inc. Full disclaimer Copyright © 2025 CME Group Inc.
